Brought to you by 
Abbott gets global rights to Neurocrine's elagolix
19 Nov 2019
Executive Summary
Neurocrine Biosciences Inc. (developing treatments for neurological and endocrine diseases) has licensed Abbott Laboratories Inc. exclusive worldwide rights to develop and commercialize elagolix and next-generation gonadotropin-releasing hormone (GnRH) antagonists for women's and men's health.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abbott gets global rights to Neurocrine's elagolix
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice